ATRC News and Press, AtriCure Inc. From 04/17/20

The stock market's tumble in mid-March was driven by indiscriminate selling caused by an awakening to the possibility of double-digit unemployment and up to a 30% drop in second quarter gross domestic product ((GDP)), coupled with changes in margin requirements resulting in forced liquidation....

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2020 financial results on Wednesday, April 29, 2020. AtriCure will host a conference call ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that results from the CONVERGE IDE trial have been accepted for presentation in the late-breaking abstract sessions at the Heart Rhyt...

Citing COVID-19 disruptions, AtriCure (NASDAQ: ATRC ) is withdrawing its previously issued financial guidance for 2020. More news on: AtriCure, Inc., Healthcare stocks news, , Read more ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the first quarter 2020 and provided updates in response to the COVID-19 pandemic. “Throu...

AtriCure, Inc. (ATRC) Q4 2019 Results Earnings Conference Call February 18, 2020 04:30 PM ET Company Participants Lynn Lewis - Gilmartin Group, Investor Relations Mike Carrel - President and Chief Executive Officer Andy Wade - Chief Financial Officer Conference Call Participan...

Image source: The Motley Fool. AtriCure Inc   (NASDAQ: ATRC) Q4 2019 Earnings Call Feb 18, 2020 , 4:30 p.m. ET Operator Continue reading

AtriCure (NASDAQ: ATRC ): Q4 Non-GAAP EPS of -$0.37 beats by $0.03 ; GAAP EPS of -$0.42 in-line. More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

2019 Worldwide revenue of $230.8 million – an increase of 14.5% year over year 2019 U.S. revenue of $185.8 million – an increase of 14.6% year over year 2019 International revenue of $45.0 million – an increase of 13.9% year over year AtriCure, Inc . ( N...

BTIG Research has restarted coverage on the following: More news on: Abbott Laboratories, Abiomed, Inc., AtriCure, Inc., Healthcare stocks news, , Read more ...